

LABORATORY CORP OF AMERICA HOLDINGS
 Form 4
 February 07, 2007

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
LAI GOLDMAN MYLA

2. Issuer Name and Ticker or Trading Symbol
LABORATORY CORP OF AMERICA HOLDINGS [LH]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
430 SOUTH SPRING STREET
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2007

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
EVP & Chief Medical Officer

BURLINGTON, NC 27215

(City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| | | | | (A) or (D) | Price | | |
| Common Stock | 02/05/2007 | | F ⁽¹⁾ | 830 | D \$ 73.53 | 35,273.405 | D |
| | | | | | | (2) (3) | |
| Common Stock | 02/05/2007 | | S ⁽⁴⁾ | 155 | D \$ 73.5 | 35,118.405 | D |
| | | | | | | (2) (3) | |
| Common Stock | 02/05/2007 | | S ⁽⁴⁾ | 155 | D \$ 73.25 | 34,963.405 | D |
| | | | | | | (2) (3) | |
| Common Stock | 02/05/2007 | | S ⁽⁴⁾ | 156 | D \$ 73.16 | 34,807.405 | D |
| | | | | | | (2) (5) | |
| Common Stock | 02/05/2007 | | S ⁽⁴⁾ | 156 | D \$ 73.15 | 34,651.405 | D |
| | | | | | | (2) (3) | |

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 4

| | | | | | | | | |
|--------------|------------|------------------|-----|---|----------|-----------------------|---|-------------|
| Common Stock | 02/05/2007 | S ⁽⁴⁾ | 158 | D | \$ 73.12 | 34,493.405 (2) (3) | D | |
| Common Stock | 02/05/2007 | S ⁽⁴⁾ | 156 | D | \$ 73.1 | 34,337.405 (2) (3) | D | |
| Common Stock | 02/05/2007 | S ⁽⁴⁾ | 155 | D | \$ 73.07 | 34,182.405 (2) (3) | D | |
| Common Stock | 02/05/2007 | S ⁽⁴⁾ | 155 | D | \$ 73.06 | 34,027.405 (2) (3) | D | |
| Common Stock | 02/05/2007 | S ⁽⁴⁾ | 310 | D | \$ 73 | 33,717.405 (2) (3) | D | |
| Common Stock | | | | | | 2,000 (6) | I | By Daughter |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned (Instr. 5) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|--|
| | | | | | | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| | | | | | | Code | V (A) (D) | | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|--------------------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| LAI GOLDMAN MYLA 430 SOUTH SPRING STREET BURLINGTON, NC 27215 | | | EVP & Chief Medical Officer | |

Signatures

By: /s/ BRADFORD T. SMITH, Attorney-in-Fact for Myla
Lai-Goldman

02/07/2007

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Stock withholding to satisfy tax and withholding obligations.
- (2) Amount shown reflects a 2-for-1 stock split effective on May 10, 2002.
- (3) Amount includes 53,121 shares acquired on December 31, 2006 under the Laboratory Corporation of America Holdings 1997 Employee Stock Purchase Plan.
- (4) Pursuant to a plan in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934.
- (5) Amount includes 17,858 shares acquired on December 31, 2006 under the Laboratory Corporation of America Holdings 1997 Employee Stock Purchase Plan.
- (6) Beneficial ownership of these shares is disclaimed.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.